For the roughly 80 million people worldwide living with glaucoma, daily life often means watching the world slowly close in.

Key Takeaways New research helps explain why cancer of the pancreas doesn't respond well to existing cancer drugsTests of an ...

A Survival God for the Age of Abundance,” Peter H. Diamandis and Steven Kotler explore what it means to be human in a world ...

From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...

Researchers have developed a modified version of the CRISPR gene-editing tool that in early laboratory experiments suggests ...

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...

Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies ...

The data to be presented show that Geminii's bioelectronic therapy slowed tumor growth, extended survival, and enhanced the activity of chemoradiation in multiple preclinical NSCLC models without ...

An innovative gene-editing strategy could establish a new way for the body to manufacture therapeutic proteins—including ...

Pancreatic cancer is often detected in late stages due to its location in the body. Tumors grow undetected within the gut and ...

Cancer drugs are designed to shut tumors down. But sometimes, in the very act of attacking a tumor, treatment can also help a small fraction of cancer cells become harder to kill. A new study from ...

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications; First-in-class METTL3 inhibitor reprograms malignant progenitor cells by modu ...